Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

GE healthcare & PhotoCure announce extension of bladder cancer licensing partnership to US market

AZDEL : 21 August, 2007  (Company News)
GE Healthcare, a unit of General Electric Company today announced that GE Healthcare has exercised the exclusive option to license PhotoCure's product Hexvix(R) (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and monitoring of bladder cancer, for the US market.
GE Healthcare, a unit of General Electric Company today announced that GE Healthcare has exercised the exclusive option to license PhotoCure's product Hexvix(R) (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and monitoring of bladder cancer, for the US market. This is an extension of the agreement signed earlier this year that afforded GE Healthcare exclusive global rights outside of the Nordic region to market and distribute PhotoCure's product Hexvix. PhotoCure continues to be responsible for manufacturing and Nordic distribution of the product. This license, which is subject to government approval related to competition laws in the US, grants GE the right to market and sell Hexvix in the United States pending U.S. Food and Drug Administration approval of the drug for use.


'We believe our partnership with PhotoCure will result in significant patient benefit in the diagnosis and management of bladder cancer,' said Daniel L. Peters, President and CEO of Medical Diagnostics at GE Healthcare. 'This partnership underscores GE Healthcare's commitment to addressing the unmet clinical needs of physician customers and to enhancing the quality of patient care through new approaches to the diagnosis and monitoring of disease.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo